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Abstract
Individuals with type 2 diabetes (T2D) and dyslipidemia are at an increased risk of cardiovascular 
disease. Fibrates are a class of drugs prescribed to treat dyslipidemia, but variation in response has 
been observed. To evaluate common and rare genetic variants that impact lipid responses to 
fenofibrate in statin-treated patients with T2D, we examined lipid changes in response to 
fenofibrate therapy using a genomewide association study (GWAS). Associations were followed-
up using gene expression studies in mice. Common variants in SMAD3 and IPO11 were 
marginally associated with lipid changes in black subjects (P < 5 × 10−6). Rare variant and gene 
expression changes were assessed using a false discovery rate approach. AKR7A3 and HSD17B13 
were associated with lipid changes in white subjects (q < 0.2). Mice fed fenofibrate displayed 
reductions in Hsd17b13 gene expression (q < 0.1). Associations of variants in SMAD3, IPO11, 
and HSD17B13, with gene expression changes in mice indicate that transforming growth factor-
beta (TGF-β) and NRF2 signaling pathways may influence fenofibrate effects on dyslipidemia in 
patients with T2D.
Dyslipidemia is a significant risk factor for cardiovascular disease (CVD), which is the 
leading cause of death worldwide.1 In the United States, it is estimated that 33.5% of adults 
have high low-density lipoprotein (LDL), and only 48.1% of those individuals are currently 
being treated.2 Individuals with type 2 diabetes (T2D) commonly express a dyslipidemia, 
characterized by high triglycerides, low high-density lipoprotein (HDL), and an increase in 
cholesterol poor, small LDL, and are 2–4 times more likely to develop heart disease than 
nondiabetic individuals.2
Fibrates, a class of medications used to treat individuals with dyslipidemia by activating the 
peroxisome proliferator-activated receptor-alpha (PPARα), increases HDL and lowers 
triglycerides and LDL. Meta-analyses of several large clinical trials indicated that treatment 
with fibrates decrease the number of nonfatal myocardial infarctions, although they did not 
decrease all-cause mortality.3,4 Statins are the first-line treatment to lower LDL to prevent 
CVD.5 Fibrates are generally not recommended to reduce CVD because of a lack of 
demonstrated benefit, although they are recommended for the management of 
hypertriglyceridemia.6 Specifically, fenofibrate is recommended in the context of statin 
therapy because of lower risk of interference with statin metabolism and myopathy.5,6
One goal of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) clinical trial 
was to compare the benefits and risks of treatment strategies for intensively managing 
dyslipidemia with a combined statin and fenofibrate therapy vs. treatment with statin alone, 
whereas simultaneously targeting normal glycemia and blood pressure vs. standard targets in 
individuals with T2D at high risk for CVD.7,8 The ACCORD trial followed 10,251 
participants for up to 8 years at 77 clinical centers in the United States and Canada. Overall, 
no statistically significant benefits were observed for patients on the combined CVD 
endpoint of time to first heart attack, stroke, or CVD mortality. In addition, there was an 
increase in mortality in participants receiving intensive glycemia control.9–12 Despite the 
lack of overall positive findings, interindividual variation in response to the different 
treatments in ACCORD was observed. Such variation to fibrate lipid response has been 
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observed in a number of studies13–15 and suggests that genetic markers of drug response 
may be important biomarkers for more targeted and personalized treatment strategies.
Previous studies have also investigated the role of genetic variation in fibrate lipid response 
with the majority of studies focused on candidate gene approaches to identify common or 
rare variants associated with differential responses.16–19 Here, we performed genomewide 
and exome-wide genotyping on all consenting individuals in the ACCORD study prescribed 
fenofibrate (n = 1,264). We previously reported a genomewide association study (GWAS) of 
fenofibrate drug response from a meta-analysis of subjects of European ancestry in 
ACCORD and the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) study.14 
Here, we expand the analysis of ACCORD participants to include other ethnicities, using 
combined data from a genomewide single nucleotide polymorphism (SNP) array, and an 
exome chip array with >1.2 million combined genotyped SNPs and rare variant analysis for 
SNPs with minor allele frequencies (MAFs) <3% for changes in LDL, HDL, triglycerides 
(TGs), and total cholesterol (TC). Our results indicate interesting and potentially impactful 
associations, and we use mouse studies to test the hypotheses generated by the gene-
mapping analysis. To our knowledge, this is the first GWAS of fenofibrate lipid response in 
multiple ethnicities, and the first exome-wide interrogation of fibrate drug response.
Although the results of the association mapping experiment can point to interesting biology, 
functional follow-up is a crucial step to support association analyses. In the current study, we 
considered the GWAS to be a hypothesis generating exercise to prioritize genes for further 
functional interrogation. We subsequently evaluated the genes identified through association 
analysis in two mouse gene expression studies, and demonstrate that many of the genes 
discovered in the association analysis play a significant role in fibrate drug response.
RESULTS
A total of 1,264, 781, and 138 subjects were included in the common and rare variant 
analyses for all races combined, white, and black cohorts, respectively. Variation in response 
was observed for all phenotypes: HDL, LDL, TC, and TG (Figure 1). Distributions of 
response variation for white and black cohorts individually can be found in Supplementary 
Figures S1 and S2. The mean change in HDL was 3.16 mg/dL (95% confidence interval [CI] 
= 2.78–3.53) for all races combined, 3.11 mg/dL (95% CI = 2.62–3.60) for white subjects 
only, and 2.80 mg/dL (95% CI = 1.73–3.86) for black subjects only. The mean change in 
LDL was −10.64 mg/dL (95% CI = −12.48 to −8.79) for all races combined, −9.31 mg/dL 
(95% CI = −11.68 to −6.95) for white subjects only, and −10.83 mg/dL (95% CI = −16.73 to 
−4.94) for black subjects only. The mean change in TG was −45.23 mg/dL (95% CI = 
−50.27 to −40.28) for all races combined, −52.04 mg/dL (95% CI = −58.31 to −45.78) for 
white subjects only, and −34.43 mg/dL (95% CI = −46.96 to −21.91) for black subjects only. 
The mean change in TC was −16.10 mg/dL (95% CI = −18.27 to −13.92) for all races 
combined, −16.14 mg/dL (95% CI = −18.93 to −13.35) for white subjects only, and −14.51 
mg/dL (95% CI = −21.13 to −7.88) for black subjects only.
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Common variant analysis
A total of 852,426 genotyped and 7,277,412 imputed variants had MAFs >3% and were 
included in the common variant analysis. When all races were combined or white subjects 
were analyzed, no SNPs met the threshold for genomewide significance (P < 5 × 10−8). 
When all races were combined, 8 SNPs associated with TG (genes: BEST3, 
LOC105371270, and RPGRIP1L; Supplementary Figure S3), 34 SNPs associated with TC 
(genes: FGF14, PRRX1, MRPL12, ZNF775, and FBXL7; Supplementary Figure S4), 1 SNP 
associated with HDL (no known genes; Supplementary Figure S5), and 2 SNP associated 
with LDL (genes: FGF14 and MRPL12; Supplementary Figure S6) reached the threshold for 
suggestive significance (P < 1 × 10−6). For white subjects only, 11 SNPs associated with TG 
(genes: LOC105371270 and RPGRIP1L; Supplementary Figure S7), 11 SNPs associated 
with TC (genes: MAU2 and PBX4; Supplementary Figure S8), 0 SNPs associated with HDL 
(Supplementary Figure S9), and 8 SNP associated with LDL (genes: PBX4, SNX7, and 
MAU2; Figure 2) reached the threshold for suggestive significance (P < 1 × 10−6). When 
black subjects were analyzed separately, 6 SNPs were significantly associated (P < 5 × 10−8) 
with TG (genes: LRFN2, LINC00333, and BCL9), and 55 SNPs reached suggestive 
significance (P < 1 × 10−6) with TG (genes: GLIS3, CCDC149, LINGO2, SNHG17, 
LOC105370782, TTLL8, RHOBTB1, and LOC101927866; Supplementary Figure S10). 
Seven SNPs were significantly associated (P < 5 × 10−8) with TC (genes: CLN8 and 
BICC1), and 108 SNPs reached suggestive significance (P < 1 × 10−6) with TC (genes: 
ST6GALNAC3, LOC105372744, SCGN, LOC102724378, NRXN1, LCT, LOC102724680, 
RBM19, MCM6, DARS, TRIOBP, DARS-AS1, PEX5L, LOC102724680, and NLGN1; 
Supplementary Figure S11). One SNP was significantly associated (P < 5 × 10−8) with HDL 
(gene: MSH3), and 8 SNPs reached suggestive significance (P < 1 × 10−6) with HDL (genes: 
TGFBR3, LOC105373670, STX8, and CELSR1; Supplementary Figure S12). Last, 5 SNPs 
associated with LDL (genes: BICC1, FOXP1, and PEX5L; Supplementary Figure S13) 
reached the threshold for suggestive significance (P < 1 × 10−6). Lead SNPs associated with 
HDL, LDL, TC, and TG (P < 1 × 10−6) are presented in Tables 1 and 2 and Supplementary 
Tables S14 and S15. None of the associations reported above were associated with placebo 
treatment.
Rare variant analysis
A total of 17,081 genes were tested for association with TG, TC, HDL, or LDL in all races 
combined, white subjects only and black subjects only with rare variants (MAF ≤0.03). 
When all races were combined, DCUN1D4 and DUSP3 were significantly associated (q < 
0.2) with TG. Additionally, when only white subjects were included, HARS2 was 
significantly associated with TG and HDL, HSD17B13 was significantly associated with TG 
and HDL, AKR7A3 was significantly associated with LDL and TC, and MARCH3 was 
significantly associated with TG (q < 0.2). Last, POGZ was significantly associated with TG 
in black subjects only (q < 0.2; Table 3). None of the genes reported above were associated 
with subjects treated with placebo (q = 1; Table 3).
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Functional validation
SNPs in genes in the common variant analysis with P < 1 × 10−5 or q < 0.2 in the rare 
variant analysis were compared to gene expression results in wild-type C57BL/6J mice fed 
vehicle control or fenofibrate for replication20 (REP1). Fifty-seven genes overlapped 
between the two studies, and 10 were significant in REP1 (q < 0.3; Mcm6, Smad3, 
Dcun1d4, Hecw2, Mipep, Ipo11, R3hdm1, Foxp1, Stx8, and Mapk10; Table 4). These genes 
and 3 additional genes that met our threshold for inclusion in the replication study but were 
not available in the previously published REP1 study (Hsd17b13, Pbx4, and Cyp4f39) were 
subsequently tested in REP2, a follow-up gene expression study in mice to confirm the 
changes in response to fenofibrate vs. vehicle control in liver, adipose, and skeletal muscle. 
Cyp4f39 was tested in REP2 because it is the murine homologue of CYP4F22 in humans, 
which was marginally significant for change in HDL in ACCORD (P < 1 × 10−5). All genes, 
except Mipep and Cyp4f39, were significantly changed in liver tissue in REP2 (q < 0.3), 
however, the direction of the effect was not always consistent with REP1 (Table 4). Genes 
Smad3, Ipo11, and Foxp1 were significantly decreased in both REP1 and REP2 and were 
considered to have successfully replicated the GWAS findings. Hsd17b13 and Pbx4 were 
significantly decreased in liver tissue in REP2 (q < 0.3; Table 4). REP1 was published 
previously and did not include Hsd17b13 or Pbx4, so these genes were not available for 
replication in REP1. However, both of these genes were tested in REP2. There were no 
significant results for gene expression tested in adipose or skeletal muscle (Supplementary 
Table S16).
DISCUSSION
Dyslipidemia continues to be a widespread disorder with significant health impacts 
worldwide. Although recent studies, including ACCORD, have raised questions concerning 
the role of additional lipid-lowering therapy in the context of statin to reduce cardiovascular 
events,9,21 dyslipidemia remains a significant risk factor for CVD and fibrates are commonly 
prescribed.22 In addition, it is important to understand the variation in response to 
fenofibrate in people with T2D who are at an especially high risk of developing an adverse 
cardiovascular event (e.g., stroke and myocardial infarction). We previously published a 
meta-analysis combining the results of the fenofibrate lipid response in the GOLDN cohort 
with white subjects in ACCORD, and found significant associations with SNPs in PBX4 and 
change in LDL in response to fenofibrate treatment.14 Here, we expand the previous study to 
include all races in ACCORD and black subjects only. In addition, we conduct a rare variant 
analysis for changes in HDL, LDL, TC, and TG and follow-up both common and rare 
variant GWAS findings in two studies of mice exposed to fenofibrate. Importantly, these 
functional validation studies highlight novel common and rare variants that contribute to 
variation in fenofibrate lipid response in individuals with T2D.
Combining all subjects that met our inclusion criteria in ACCORD resulted in 1,264 subjects 
available for analysis. Cytochrome P450 family 4 subfamily F member 22 (CYP4F22), was 
marginally associated with changes in HDL (P = 2.50 × 10−6, β = −0.023). CYP4F22 is part 
of the 12(R)-lipoxygenase pathway, and has been shown to produce potent PPARα agonists,
23,24 which makes SNPs in CYP4F22 biologically plausible for causing variation in HDL, 
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because PPARα is the therapeutic target of fenofibrate. Although the biological role of 
CYP4F22 is a compelling candidate for fibrate drug response, Cyp4f39, the murine 
homologue of CYP4F22, did not replicate in REP2, suggesting that the GWAS finding may 
be a false-positive, the replication may have failed due to species differences or gene 
expression may not be the appropriate test for CYP4F22 response to fenofibrate exposure.
In black subjects only, lead SNP rs142923802, located in importin 11 (IPO11) was also 
marginally associated with change in LDL (P = 1.52 × 10−6, β = 0.095). Gene expression of 
Ipo11 was significantly decreased in both REP1 (q = 0.24) and in the liver in REP2 (q = 
0.15). IPO11 codes the nuclear import receptor, importin 11, and in conjunction with 
ubiquitin-conjugating enzyme, UBE2E3, restricts KEAP1, which is a major suppressor of 
Nrf2.25 Notably, Nrf2 in mice has been shown to interact with lipogenic genes and to 
regulate hepatic lipid homeostasis.26 Moreover, Nrf2-null mice displayed reduced liver 
weight, decreased fatty acid content of hepatic triacylglycerol, and increases in serum HDL, 
and very low-density lipoprotein triglyceride. Finally, PPARγ and other genes were found to 
be direct targets of Nrf2 activation, demonstrating that Nrf2, regulated by KEAP1 and 
IPO11 in humans, modulate lipid homeostasis. Rare variants in Aldo-keto reductase 7A3, 
AKR7A3, were significantly associated with LDL in white subjects only (q = 0.08). The 
AKR family of enzymes catalyze a wide range of endogenous and exogenous chemicals, 
including glucose, steroid hormones, and lipids. Akr7a3 is transcriptionally regulated by 
Nrf2 in mice, which, in addition to IPO11 results discussed above, further supports the 
implication of Nrf2 signaling in regulating fenofibrate drug response.27,28 Previous studies 
have demonstrated that Nrf2 signaling is activated by fenofibrate through Keap1 in mice, 
and may be responsible for the protective effect of fenofibrate for oxidative stress.29 Here, 
we present evidence that SNPs located in genes in the Nrf2 signaling pathway may play an 
important role in regulating the change in LDL upon fenofibrate treatment.
In black subjects, rs12912310, located in the gene, mothers against decapentaplegic-3 
(SMAD3), was marginally associated with LDL (P = 5.75 × 10−6) and TC (P = 1.88 × 10−6). 
Smad3 expression was significantly decreased in response to fenofibrate in both REP1 (q = 
0.09) and REP2 (q = 0.19). SMAD3 is a member of the SMAD family of genes and is an 
intracellular signal transducer and transcriptional modulator activated by transforming 
growth factor-beta (TGF-β), and binds to the promoter region of many genes regulated by 
TGF-β and activates them by forming a SMAD3/SMAD4 complex.30–32 In a study by Tan 
et al.,31 SMAD3 knockout mice had lower plasma free fatty acid and glycerol, and reduced 
adiposity. The same study demonstrated that SMAD3 knockout mice had altered regulation 
of PPARγ and PPARβ. Furthermore, PPARα, the therapeutic target of fenofibrate, has been 
shown to inhibit TGF-β, which regulates SMAD2, SMAD3, and SMAD4 transcription 
factors.33 Pathways involving PPARα, TGF-β, and SMAD transcription factors are clearly 
convoluted and more research is needed to elucidate these relationships, and these results 
suggest that SMAD3 may play a role in fenofibrate lipid response. Furthermore, in black 
subjects, SNP rs1653969 located in FOXP1, was associated with a poorer LDL response to 
fenofibrate (P = 9.18 × 10−7). FOXP1 is a member of the forkhead box class of genes, which 
is a large family of transcription factors. Little is known about the role of FOXP1, but other 
FOX transcription factors (e.g., FOXO3a) have been shown to be impacted by fenofibrate 
treatment.34 Importantly, expression of Foxp1 was significantly decreased in both REP1 and 
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REP2 analysis, and additional research is needed to further elucidate the role of FOXP1 in 
fenofibrate lipid response.
When the cohort was limited to white subjects only, there was a significant association 
between LDL and the lead SNP, rs140229040, which is located in the PBX homeobox 4 
(PBX4) gene (P = 3.66 × 10−7). SNPs in this gene are part of a large region in linkage 
disequilibrium, and this region has been previously identified as being associated with LDL 
cholesterol.35–37 We reported this finding previously with a meta-analysis using the GOLDN 
cohort.12 This gene was not available for follow-up in REP1 but was significantly decreased 
in liver tissue of mice exposed to fenofibrate in REP2 (q = 0.12). Interestingly, functional 
validation in the study by Holmen et al.38 identified TM6SF2, which is in high linkage 
disequilibrium with PBX4, as being the gene functionally responsible for regulating LDL.
We also tested rare variants for associations with LDL, HDL, TG, and TC. Six unique genes 
(POGZ, HSD17B13, HARS2, DCUN1D4, DUSP3, and MARCH3) were significantly 
associated with TG. Gene expression changes for DCUN1D4 was significantly altered in 
both REP1 and REP2, but with opposing directions (q < 0.3). Very little is known about the 
function of DCUN1D4, with studies mostly conducted in C. elegans and S. cerevisiae.39 In 
addition to TG, HSD17B13 was also associated with change in HDL in white subjects only 
(q < 0.2). Importantly, rare genetic variants in hydroxysteroid 17-beta dehydrogenase 3 
(HSD17B13) were significantly associated with TG and HDL in white subjects (q < 0.05) 
and mice fed fenofibrate displayed a significant reduction in Hsd17b13 gene expression 
when administered fenofibrate vs. vehicle control in REP2 (q = 5.93 × 10−4; Supplementary 
Table S6). HSD17B13, an isoform of 17 beta-hydroxysteroid dehydrogenase (17βHSD), is 
highly expressed in the testis, and is also expressed in the liver.40 However, other isoforms of 
17βHSD are expressed in many tissues. Unlike many of the other isoforms of 17βHSD, only 
recently has the role of 17βHSD13 become clear. Human fatty liver samples have shown that 
17βHSD13 is upregulated in lipid droplet fractions.41 Furthermore, 17βHSD13 was 
significantly upregulated in the livers of both diabetic mice and mice fed high-fat diets, 
suggesting that 17βHSD13 may play an important role in the pathogenesis of fatty liver in 
both mice and in humans and may also be relevant in diabetes. In the same study, 
overexpression of Hsd17b13 in C57BL/6 mouse livers increased lipogenesis and lipid 
accumulation and overexpression of 17βHSD13 increased lipid droplet formation in human 
cell lines.41 Interestingly, in the mouse model, overexpression of Hsd17b13 did not increase 
plasma TG or TC levels.41 Although the results presented by Su et al.41 demonstrate a clear 
role of 17βHSD13 in nonalcoholic fatty liver disease, the results presented here mark the 
first time that rare variant SNPs in 17βHSD13 have been shown to impact the lipid lowering 
effects of fenofibrate.41 Additional research is needed to fully elucidate the relationship 
between 17βHSD13 and fenofibrate lipid response. It is possible that 17βHSD13 may 
become an important biomarker in precision medicine initiatives for more targeted treatment 
of fenofibrate.
These findings occurred in subjects with T2D treated with statins, which is more clinically 
representative than fenofibrate monotherapy, because fibrates are commonly prescribed with 
statin therapy.42 Furthermore, these associations were not observed in subjects treated with 
placebo and statin, lending support for these associations with fenofibrate drug response. 
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Although several GWAS findings were replicated in two functional studies, those studies 
were conducted using a mouse model that may not be applicable to human subjects, and not 
all genes with GWAS associations here were available for gene expression follow-up. 
Additionally, gene expression may not be the most relevant mechanism, as numerous ways 
exist for SNPs to impact drug response. Future studies will require larger cohorts and further 
functional work in relevant tissues to elucidate the pathways in which fenofibrate and 
PPARα alter lipid concentrations.
We have identified novel common variants in black subjects located in several genes (e.g., 
SMAD3 and IPO11) and rare variants (e.g., HSD17B13) that explain lipid variation in 
response to fenofibrate treatment in individuals with T2D treated with statins. These findings 
were further supported by changes in gene expression in mice and provide novel findings 
that explain variation in fenofibrate lipid response in individuals with T2D.
MATERIALS AND METHODS
Study participants
The ACCORD trial (clinicaltrials.gov-NCT00000620) was a double 2 × 2 factorial design, 
consisting of 10,251 recruited subjects with T2D and either a history of CVD or at least two 
known risk factors for CVD, such as documented atherosclerosis, albuminuria, dyslipidemia, 
hypertension, smoking, or obesity.7 Subjects were randomized to either intensive or standard 
glycemia treatment strategies (targeting HbA1c <6.0 vs. HbA1c between 7.0 and 7.9). Over 
80% of subjects in the ACCORD study consented to being genotyped. There were 5,518 
subjects who were further randomized to intensive vs. standard lipid management 
(fenofibrate vs. placebo, with all subjects on simvastatin). Each ACCORD participant 
provided written informed consent using procedures reviewed and approved by each clinical 
site’s local institutional review board and based on a template provided by the study group 
that was approved and subsequently centrally monitored by the Coordinating Center and the 
National Heart, Lung, and Blood Institute (IRB: FWA00003429). Entry criteria and 
additional information about the lipid subtrial and patient selection are described in the 
Supplementary Material online. As in the prior ACCORD and GOLDN meta-analyses, 
fenofibrate lipid response was calculated as:
where a is the pretreatment measurement of HDL, LDL, TC, or TG, and b is the on-
treatment measurement of HDL, LDL, TC, or TG. After subsetting patients from the lipid 
subtrial based on consent, genotyping, drug response criteria, and quality control (see below) 
of DNAs extracted from these samples, the population for the current study included 1,264 
subjects. These subjects included individuals that self-identified as white, black, Hispanic, 
Asian, and other.
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Genotyping and quality control
Genomic DNA extraction and cell preparations are described in the Supplementary Material. 
Genomewide genotyping was performed in two independent laboratories on different 
platforms: 6,085 unique samples, composed of those ACCORD participants who consented 
to genetic studies conducted by any investigator, were genotyped at the University of 
Virginia on Illumina HumanOmniExpressExome-8 version 1.0 chips (set 1)43; 8,174 unique 
samples, including the above 6,085 samples plus 2,089 samples from ACCORD participants 
who consented to genetic studies only if conducted by ACCORD investigators were 
genotyped at the University of North Carolina on Affymetrix Axiom Biobank1 chips (set 2). 
Additional information regarding the merging of set 1 and set 2, imputation, and quality 
control can be found in the Supplementary Material.
Covariate selection
Here, we take a combined approach to variable selection to address potential confounding 
variables. A substantial proportion of the cohort was taking lipid-lowering medications at the 
time baseline lipid measurements were taken (e.g., 63% were on a statin prior to entering the 
trial). Statin, additional concomitant medications, and nondrug covariates (e.g., age, gender, 
body mass index, and smoking status) were incorporated into the model, as previously 
described in Graham & Rotroff et al.44 and is described in the Supplementary Material. A 
full list of covariate names and descriptions can be found in Supplementary Table S1.
Common variant analysis
Association between a phenotype, selected, and forced covariates, and a single common 
variant (MAF >3%) was tested with an additive genetic model using linear regression in the 
PLINK software for genotyped variants.45 Imputed variants were tested using a linear 
regression model in the statistical programming language, R, where gi=pi(Aa) + 2pi(aa) is 
the dosage score computed from the posterior probabilities for genotypes Aa and aa.45,46 For 
SNPs that were only genotyped in set 1 subjects and were imputed in set 2 subjects, 
association tests results were combined by meta-analysis using PLINK.45 Tables and figures 
specify whether each SNP association was genotyped, imputed, or meta-analyzed. The 
results from the common variant tests were considered statistically significant based on a P < 
5 × 10−8 and P < 1 × 10−6 was considered the threshold for suggestive significance. To 
maximize the likelihood of finding genes expression altered by fenofibrate exposure, a more 
liberal threshold of P < 1 × 10−5 was used only for functional validation, as described below. 
Additional information regarding the common variant analysis can be found in the 
Supplementary Material.
Rare variant analysis
We implemented a suite of five rare variant tests that can be divided into two classes, burden 
and nonburden approaches, as previously described.47 Burden tests collapse a set of rare 
variants from a gene into a single variable, which is then tested for association with a 
phenotype. However, simple burden tests do not account for the direction (positive or 
negative association) of a rare variant effect.48 One nonburden rare variant test that allows 
for different directions and magnitudes of effects for each variant is the sequence kernel 
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association test (SKAT).48 The balance between SKAT and burden tests was addressed using 
the optimal test, SKAT-O, which aims to optimize the combination of the two approaches. 
Gene annotations were performed using Ensemble (GRCh37.p13), which mapped the 
232,678 rare variants (MAF ≤3%) genotyped in set 1 subjects to 17,081 total genes. 
Subsequently, the combined P value was corrected for multiple comparisons with an false 
discovery rate (FDR) approach using the R package, qvalue (version 1.36.0) and q < 0.2 was 
considered to be statistically significant.49 Additional details regarding the rare variant 
analysis implemented here can be found in Marvel & Rotroff et al.47 and the Supplementary 
Material.
Placebo analysis
Study protocols for those receiving placebo in the lipid subtrial of ACCORD were the same 
as the fibrate arm of the trial, except that placebo was administered instead of fenofibrate. To 
confirm that the results were associated with fibrate and not placebo or statin, we conducted 
common and rare variant associations using the same analysis workflow, covariates, and 
models as described above for all races combined (n = 1,336), white (n = 908), and black 
subjects (n = 186). The results from the placebo analysis are included along with the 
fenofibrate results in Tables (1–3) and Supplementary Tables S14 and S15.
Mouse gene expression validation
We investigated gene expression changes in wild-type C57BL/6J mice administered 
fenofibrate compared with mice administered vehicle control, as described by Liu et al.20 to 
provide additional validation for common and rare variant associations with fenofibrate lipid 
response identified (REP1). To maximize the likelihood of finding genes with expression 
changes due to fenofibrate exposure, we expanded the genes chosen for evaluation to include 
those with common variant associations P < 1 × 10−5, where the variants were annotated as 
being in genes according to the National Center for Biotechnology Information database 
using the rsnps package,50 and genes with q < 0.2 in the rare variant tests. An additional 
follow-up replication study was conducted at the University of Kentucky (REP2) to try and 
further validate the findings in REP1 and include additional genes identified in the 
ACCORD analysis that were not available in the previously published data in REP1. 
Additional details regarding the mouse gene expression methods can be found in the 
Supplementary Material. Furthermore, the gene expression results of Rab27b, a gene 
identified in an interim analysis of only set 2 data, and was not significant after merging set 
1 and set 2 data (q > 0.2) is presented in the Supplementary Material.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
☑ Fibrates are a class of drugs commonly prescribed to lower serum lipid levels; 
however, individual variation in response to fenofibrates has been observed and 
drivers of this variation are not well understood.
WHAT QUESTION DID THIS STUDY ADDRESS?
☑ Here, we evaluate the association of common and rare genetic variants with 
variation in response to fenofibrate treatment in individuals with T2D.
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
☑ We demonstrate novel associations of common genetic variants in SMAD3 and 
IPO11 genes in black subjects, and rare variants in AKR7A3 and HSD17B13 in 
white subjects were associated with variation in fibrate lipid response. We then 
support these findings using gene expression in a mouse model.
HOW THIS MIGHT CHANGE CLINICAL PHARMACOLOGY OR 
TRANSLATIONAL SCIENCE
☑ Our findings highlight genetic variants in TGF-β and NRF2 signaling pathways 
that may influence fenofibrate effects on dyslipidemia in individuals with T2D. 
This insight could help to identify patients for more targeted treatment strategies 
or elucidate novel therapeutic targets.
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Figure 1. 
Distributions of fenofibrate response on lipid measurements in subjects of all combined 
races (N = 1264). (a) Log-ratio of the change in high-density lipoprotein (HDL; mg/dL). (b) 
Log-ratio of the change in low-density lipoprotein (LDL; mg/dL). (c) Log-ratio of the 
change in triglycerides (mg/dL). (d) Log-ratio of the change in total cholesterol (mg/dL).
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Figure 2. 
Manhattan plot of single-nucleotide polymorphism associations with change in low-density 
lipoprotein in white subjects only. [Color figure can be viewed at wileyonlinelibrary.com]
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Figure 3. 
Gene expression in mice exposed to fenofibrate vs. vehicle control in (a) adipose tissue, (b) 
skeletal muscle, and (c) liver tissue. ***False discovery rate (FDR) P value < 0.01; **FDR P 
value < 0.1; *FDR P value < 0.2. [Color figure can be viewed at wileyonlinelibrary.com]
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